Thymagen

Thymagen (also spelled Thymogen in some publications) is a short peptide bioregulator developed by the Khavinson group as a synthetic representative of the immunoregulatory activity of thymic extracts. The compound is reported as the dipeptide Glu-Trp (EW) — one of the shortest active sequences in the Khavinson bioregulator family. It is proposed to target thymic epithelial cells and peripheral T cells to support immune function, with applications in age-related immune decline, post-illness immune recovery, and chronic infectious disease contexts.

Russian clinical-observational studies have evaluated Thymagen and the older related compound Thymalin across decades of use in geriatric, infectious-disease, and recovery contexts. The two compounds are partially redundant — Thymalin is a longer peptide complex derived from thymic extract, while Thymagen / Thymogen is the shorter synthetic dipeptide developed to capture the same activity in a more drug-like molecule.

Thymagen is sold by research-chemical vendors outside Russia. Western clinical validation is essentially absent. Choice between Thymagen, Thymalin, Crystagen, and Vilon in Russian practice often reflects clinician preference and historical familiarity rather than evidence-based differentiation.

Thymalin was the original Khavinson thymic preparation, developed in the 1980s from bovine thymic extract. Thymagen / Thymogen was developed subsequently as a synthetic short-peptide representative of the thymic peptide complex's activity, with the Glu-Trp dipeptide identified as a bioactive component. Both compounds have been used in Russian clinical practice for several decades.